Role of anti-DNA auto-antibodies as biomarkers of response to treatment in systemic lupus erythematosus patients: hypes and hopes. Insights and implications from a comprehensive review of the literature

References

• Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605–620.
   PubMed Web of Science ®Google Scholar
• Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(2):144–150.
   PubMed Web of Science ®Google Scholar
• Ungprasert P, Sagar V, Crowson CS, et al. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American college of rheumatology and the 2012 systemic lupus international collaborating clinics classification criteria. Lupus. 2017;26(3):240–247.
   PubMed Web of Science ®Google Scholar
• Ferucci ED, Johnston JM, Gaddy JR, et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007–2009. Arthritis Rheumatol. 2014;66(9):2494–2502.
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan lupus epidemiology and surveillance program. Arthritis Rheumatol. 2014;66(2):369–378.
   PubMed Web of Science ®Google Scholar
• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.
   PubMed Web of Science ®Google Scholar
• Damiani G, Pigatto PDM, Marzano AV, et al. Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. Clin Rheumatol. 2019. [Epub ahead of print]. DOI:10.1007/s10067-019-04536-y.
   Web of Science ®Google Scholar
• Podolska MJ, Biermann MH, Maueröder C, et al. Inflammatory etiopathogenesis of systemic lupus erythematosus: an update. J Inflamm Res. 2015;8:161–171.
   PubMed Web of Science ®Google Scholar
• Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun. 2019;96:1–13.
   PubMed Web of Science ®Google Scholar
• Yang J, Yang X, Zou H, et al. Oxidative stress and treg and Th17 dysfunction in systemic lupus erythematosus. Oxid Med Cell Longev. 2016;2526174.
   Google Scholar
• Fujii J, Kurahashi T, Konno T, et al. Oxidative stress as a potential causal factor for autoimmune hemolytic anemia and systemic lupus erythematosus. World J Nephrol. 2015;4(2):213–222.
   PubMedGoogle Scholar
• Lightfoot YL, Blanco LP, Kaplan MJ. Metabolic abnormalities and oxidative stress in lupus. Curr Opin Rheumatol. 2017;29(5):442–449.
   PubMed Web of Science ®Google Scholar
• Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28(5):497–505.
   PubMed Web of Science ®Google Scholar
• Mak A, Tay SH. Environmental factors, toxicants and systemic lupus erythematosus. Int J Mol Sci. 2014;15(9):16043–16056.
   PubMed Web of Science ®Google Scholar
• Doaty S, Agrawal H, Bauer E, et al. Infection and lupus: which causes which? Curr Rheumatol Rep. 2016;18(3):13.
   PubMed Web of Science ®Google Scholar
• Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res. 2018;32(2):188–205.
   Web of Science ®Google Scholar
• Tipping PG, Buchanan RC, Riglar AG, et al. Measurement of anti-DNA antibodies by ELISA: a comparative study with crithidia and a farr assay. Pathology. 1991;23(1):21–24.
   PubMed Web of Science ®Google Scholar
• Duus K, Draborg AH, Güven E, et al. A fluorescence sedimentation assay for dsDNA antibodies. Scand J Clin Lab Invest. 2017;77(6):465–471.
   PubMed Web of Science ®Google Scholar
• Mummert E, Fritzler MJ, Sjöwall C, et al. The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. J Immunol Methods. 2018;459:11–19.
   PubMed Web of Science ®Google Scholar
• Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53(6):424–432.
   PubMed Web of Science ®Google Scholar
• Gensous N, Marti A, Barnetche T, et al. Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. Arthritis Res Ther. 2017;19(1):238.
   PubMedGoogle Scholar
• Mina R, Brunner HI. Pediatric lupus–are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus. Rheum Dis Clin North Am. 2010;36(1):53–80.
   PubMed Web of Science ®Google Scholar
• Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum. 2015;Dis.74:1706–1713.
   Google Scholar
• Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122(1):62–74.
   PubMed Web of Science ®Google Scholar
• Liu B, Ou Q, Tang Y, et al. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis. Clin Rheumatol. 2019. [Epub ahead of print]. DOI:10.1007/s10067-019-04596-0.
   Web of Science ®Google Scholar
• Gheita TA, Abaza NM, Hammam N, et al. Anti-dsDNA titre in female systemic lupus erythematosus patients: relation to disease manifestations, damage and antiphospholipid antibodies. Lupus. 2018;27(7):1081–1087.
   PubMed Web of Science ®Google Scholar
• Yang TH, Wu TH, Chang YL, et al. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus. Clin Nephrol. 2018;89(4):277–285.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Kameda H, Nagasawa H, et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol. 2007;17(2):92–97.
   PubMedGoogle Scholar
• Li Y, Feng X. Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus. 2018;27(1):60–65.
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013;22(11):1135–1141.
   PubMed Web of Science ®Google Scholar
• Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018;27(6):1007–1011.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Zou K, et al. Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. Rheumatol Int. 2017;37(7):1089–1099.
   PubMed Web of Science ®Google Scholar
• Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29(7):771–775.
   PubMed Web of Science ®Google Scholar
• Bijl M, Horst G, Bootsma H, et al. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis. 2003;62(6):534–539.
   PubMed Web of Science ®Google Scholar
• Parodis I, Johansson P, Gomez A, et al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019;pii: kez191. [Epub ahead of print]. DOI:10.1093/rheumatology/kez191
   PubMedGoogle Scholar
• Roth DA, Thompson A, Tang Y, et al. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus. 2016;25(4):346–354.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(2):300–309.
   PubMed Web of Science ®Google Scholar
• Ishii T, Tanaka Y, Kawakami A, et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018;28(6):986–992.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):323–331.
   PubMed Web of Science ®Google Scholar
• Furie R, Wang L, Illei G, et al. Systemic Lupus Erythematosus (SLE) responder index response is associated with global benefit for patients with SLE. Lupus. 2018;27(6):955–962.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883–889.
   PubMed Web of Science ®Google Scholar
• Boedigheimer MJ, Martin DA, Amoura Z, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4(1):e000226.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–552.
   PubMed Web of Science ®Google Scholar
• Tew GW, Rabbee N, Wolslegel K, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19(2):146–157.
   PubMed Web of Science ®Google Scholar
• Roccatello D, Sciascia S, Rossi D, et al. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant. 2011;26(12):3987–3992.
   PubMed Web of Science ®Google Scholar
• Jónsdóttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330–334.
   PubMed Web of Science ®Google Scholar
• Hickman RA, Hira-Kazal R, Yee CS, et al. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol. 2015;34(2):263–271.
   PubMed Web of Science ®Google Scholar
• Reynolds JA, Toescu V, Yee CS, et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009;18(1):67–73.
   PubMed Web of Science ®Google Scholar
• Aguiar R, Araújo C, Martins-Coelho G, et al. Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years. Arthritis Care Res (Hoboken). 2017;69(2):257–262.
   PubMed Web of Science ®Google Scholar
• Schroeder JO, Zeuner RA, Euler HH, et al. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol. 1996;23(1):71–75.
   PubMed Web of Science ®Google Scholar
• Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin–clinical and serologic response. Lupus. 1999;8(9):705–712.
   PubMed Web of Science ®Google Scholar
• Monova D, Monov S. Treatment of active lupus nephritis: intravenous immunoglobulin G versus cyclophosphamide or azathioprine. BANTAO J. 2006;4:13.
   Google Scholar
• Perricone R, De Carolis C, Kroegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford). 2008;47:646–651.
   PubMed Web of Science ®Google Scholar
• Zheng R, Gonzalez A, Yue J, et al. Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Am J Med Sci. 2019;358(2):104–114.
   PubMed Web of Science ®Google Scholar
• Cao C, Wang M, Sun J, et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol. 2017;35(3):500–507.
   PubMed Web of Science ®Google Scholar
• Infantino M, Grossi V, Benucci M, et al. The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests. Lupus. 2018;27(1):40–48.
   PubMed Web of Science ®Google Scholar
• Sowa M, Trezzi B, Hiemann R, et al. Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis. Medicine (Baltimore). 2016;95(44):e5225.
   PubMed Web of Science ®Google Scholar
• Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, et al. Development and validation of a novel evidence-based lupus multivariable outcome score for clinical trials. Arthritis Rheumatol. 2018;70(9):1450–1458.
   PubMed Web of Science ®Google Scholar
• Pisetsky DS, Rovin BH, Lipsky PE. New perspectives in rheumatology: biomarkers as entry criteria for clinical trials of new therapies for systemic lupus erythematosus: the example of antinuclear antibodies and anti-DNA. Arthritis Rheumatol. 2017;69(3):487–493.
   PubMed Web of Science ®Google Scholar